drugset / Trial / NCT03300505
ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
Phase 1
Terminated
9 enrolled
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of ARRx (also known as AZD5312) plus enzalutamide in patients with metastatic castration resistant prostate cancer.
Timeline
- Start
- 2019-05-31
- Primary completion
- 2023-01-24
- Completion
- 2023-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD5312 | Unknown | — | Intravenous |
| Background | Enzalutamide | Other / unclassified | — | Oral |